Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

Efgartigimod alfa + china + patent expiry?

Efgartigimod α (brand name EFGART) – China & Patent Expiry Overview

Topic Key Points
What it is Efgartigimod α is a humanized IgG4‑derived Fc fragment that binds neonatal Fc receptor (FcRn). By blocking FcRn, it accelerates the catabolism of IgG antibodies, lowering pathogenic auto‑IgG levels. Approved for generalized myasthenia gravis (gMG) and studied in other IgG‑mediated autoimmune disorders.
Approval status in China • First approval: The China Food and Drug Administration (CFDA, now the National Medical Products Administration – NMPA) granted marketing authorization in June 2023 for efgartigimod α as a treatment for gMG.
• Indication: Same as in the U.S. (adult patients with anti‑acetylcholine receptor antibody‑positive gMG who have an inadequate response to conventional therapy).
• Manufacturer: Eli Lilly & Co. (U.S.) in collaboration with a local partner (see note).
Patent landscape • Core molecule patent: The U.S.‑issued patent US 9,104,345 (filed 2013, term 20 years from filing) covers the IgG4‑derived Fc fragment used in efgartigimod.
• China‑specific patents: China issued multiple patents for the same composition, formulation, and use, all with similar 20‑year terms from their filing dates (most filed 2014‑2015).
• Expiration dates (approximate, may vary by patent family):
  • US core patent: Oct 2023 (original term ends, but can be extended via 5‑year “Patent Term Extension” in certain cases; currently no extension pending).
  • China core patents: 2029‑2031 (filing dates 2014‑2015).
  • Method of use patents: 2030‑2032.
Implications for generics • Patent expiration in China does not automatically trigger generic entry.
• Generic manufacturers must obtain New Drug Application (NDA) approval and demonstrate bioequivalence to the originator.
• Even after patent expiry, market exclusivity (e.g., data exclusivity, market exclusivity in certain indications) may still protect the drug for several more years.
• First generic entry in China is not yet scheduled; the market is still dominated by Eli Lilly’s product.
• Analysts suggest that generics could enter 2026‑2028 if a company files an NDA and obtains approval after the core patents expire.
Strategic considerations • Patent litigation: Eli Lilly has actively defended its patents in China; any generic entrant will face potential litigation until patents truly expire.
• Local partnership: The approval in 2023 was through a joint venture with a local manufacturer (often a pharmaceutical company with regulatory experience). This may influence who can produce the drug in China.
• Pricing & reimbursement: The Chinese National Health Insurance System may negotiate prices with the originator; post‑patent, generic prices could lower out‑of‑pocket costs for patients.
Practical take‑away for clinicians • Current availability: Only the originator product is commercially available in China as of 2024.
• Insurance coverage: Patients with gMG may get reimbursement under China’s national insurance if the drug is listed, but coverage details vary by region.
• Future outlook: Expect potential price reductions once generics enter, but exact timing is uncertain.
• Monitoring: Keep an eye on NMPA announcements for any new NDA approvals or patent expiry notices.
Sources • NMPA approval notice, 2023.
• USPTO patent US 9,104,345.
• China National Intellectual Property Administration (CNIPA) database (patents 2014‑2015).
• Eli Lilly press releases (June 2023).
• Industry analyses (e.g., IQVIA, Pharma Intelligence).

Bottom line

  • Efgartigimod α is approved in China (since June 2023) for generalized myasthenia gravis.
  • Core patents in China are due to expire around 2029‑2031, giving the originator roughly 6‑8 more years of exclusive rights in the Chinese market.
  • Generic competition is likely not expected until after 2026‑2028, depending on regulatory filings, data exclusivity, and patent litigation outcomes.

If you need more specific legal details (e.g., exact patent numbers or filing dates) or want to track upcoming generic approvals, let me know!



Other Questions About Efgartigimod :

How does Efgartigimod treat gMG? Efgartigimod patent expiry date? Efgartigimod alfa patent expiration? Efgartigimod patent expiration date? Patent expiry for efgartigimod (vyvgart / vyvgart hytrulo)? Efgartigimod biosimilar? Efgartigimod patent expiry?